Your browser is no longer supported. Please, upgrade your browser.
Advaxis, Inc.
Index- P/E- EPS (ttm)-0.20 Insider Own0.05% Shs Outstand145.64M Perf Week-5.35%
Market Cap64.79M Forward P/E- EPS next Y-0.15 Insider Trans0.00% Shs Float145.56M Perf Month-9.80%
Income-18.90M PEG- EPS next Q-0.04 Inst Own11.40% Short Float2.35% Perf Quarter8.43%
Sales3.20M P/S20.25 EPS this Y60.30% Inst Trans- Short Ratio0.58 Perf Half Y2.08%
Book/sh0.30 P/B1.57 EPS next Y11.80% ROA-39.50% Target Price- Perf Year12.70%
Cash/sh0.33 P/C1.43 EPS next 5Y- ROE-47.30% 52W Range0.26 - 1.57 Perf YTD35.36%
Dividend- P/FCF- EPS past 5Y55.60% ROI-88.00% 52W High-69.94% Beta2.26
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low78.86% ATR0.05
Employees18 Current Ratio7.00 Sales Q/Q450.00% Oper. Margin- RSI (14)46.27 Volatility9.29% 8.51%
OptionableNo Debt/Eq0.00 EPS Q/Q75.80% Profit Margin- Rel Volume0.50 Prev Close0.49
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume5.91M Price0.47
Recom2.00 SMA20-5.45% SMA50-0.69% SMA200-19.35% Volume2,956,071 Change-2.88%
Aug-03-16Reiterated Barclays Overweight $15 → $20
Sep-22-15Initiated Barclays Overweight $40
Sep-11-15Initiated Guggenheim Buy $30
Jun-16-15Reiterated H.C. Wainwright Buy $25 → $30
May-15-15Initiated Jefferies Buy $27
May-14-15Initiated MLV & Co Buy $34
Oct-23-14Initiated H.C. Wainwright Buy $8
Feb-18-14Initiated Aegis Capital Buy $18
Feb-10-14Initiated Noble Financial Buy $12
Sep-10-21 08:30AM  
Aug-11-21 08:00AM  
Jul-22-21 08:00AM  
Jul-20-21 03:45PM  
Jul-18-21 02:18AM  
Jul-16-21 09:00PM  
Jul-15-21 08:00AM  
Jul-14-21 04:01PM  
Jul-13-21 02:32PM  
Jul-11-21 08:00PM  
Jul-10-21 04:00PM  
Jul-08-21 08:57AM  
Jul-07-21 03:47PM  
Jul-06-21 02:44PM  
Jun-14-21 04:05PM  
May-19-21 05:01PM  
Apr-28-21 04:30PM  
Apr-26-21 11:07AM  
Apr-20-21 01:06PM  
Apr-12-21 08:30AM  
Apr-10-21 08:31AM  
Apr-05-21 08:00AM  
Mar-25-21 02:45PM  
Mar-23-21 11:33AM  
Mar-16-21 09:00AM  
Mar-12-21 08:00AM  
Jan-25-21 07:00AM  
Jan-19-21 08:00AM  
Dec-22-20 01:42PM  
Dec-16-20 01:05PM  
Dec-13-20 11:15PM  
Nov-27-20 12:07PM  
Nov-24-20 08:30AM  
Nov-23-20 04:05PM  
Nov-09-20 08:01AM  
Oct-26-20 08:00AM  
Oct-15-20 08:00AM  
Sep-29-20 08:30AM  
Sep-24-20 08:00AM  
Sep-10-20 08:00AM  
Sep-04-20 04:30PM  
Aug-31-20 05:00PM  
Aug-27-20 08:00AM  
Aug-05-20 09:00AM  
Aug-03-20 09:31PM  
Jun-23-20 08:00AM  
Jun-17-20 06:25AM  
Jun-11-20 08:00AM  
Jun-01-20 08:00AM  
May-14-20 08:00AM  
Mar-13-20 09:00AM  
Mar-03-20 04:01PM  
Feb-27-20 09:00AM  
Feb-20-20 08:00AM  
Feb-16-20 03:03PM  
Feb-13-20 08:00AM  
Feb-11-20 08:00AM  
Jan-30-20 09:23AM  
Jan-21-20 08:30AM  
Jan-07-20 08:00AM  
Dec-22-19 05:08PM  
Dec-20-19 08:00AM  
Dec-04-19 08:00AM  
Dec-03-19 08:00AM  
Oct-24-19 09:00AM  
Oct-10-19 08:00AM  
Oct-07-19 08:00AM  
Sep-19-19 06:36AM  
Sep-10-19 07:36AM  
Sep-09-19 08:00AM  
Aug-22-19 08:00AM  
Aug-12-19 06:30AM  
Jul-25-19 11:30AM  
Jul-24-19 07:08AM  
Jul-23-19 08:30AM  
Jul-15-19 08:00AM  
Jun-27-19 06:50AM  
Jun-21-19 10:14AM  
Jun-11-19 09:00AM  
Jun-10-19 04:05PM  
Jun-04-19 08:00AM  
May-25-19 09:48AM  
May-15-19 10:25AM  
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.